Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.
NCT02072057
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
8
Enrollment
OTHER
Sponsor class
Stopped
Poor recruiting
Conditions
Cancer Cachexia
Interventions
DRUG:
Ruxolitinib
Sponsor
Kantonsspital Aarau
Collaborators
[object Object]
[object Object]
[object Object]